When developing new compounds, Actelion values the interactive dialogue between its teams and the medical community. In this way, innovation can be translated into evidence-based medicine.
When developing new compounds, Actelion values the interactive dialogue between its teams and the medical community. In this way, innovation can be translated into evidence-based medicine.
Tracleer® (bosentan) is an oral dual endothelin receptor antagonist. Tracleer® is the only PAH therapy proven to delay disease progression, reduce severity and symptoms. Tracleer is the only oral PAH therapy with an established safety and tolerability profile in more than 80,000 patients worldwide.
Ventavis® (inhaled iloprost) is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclin (PGI2) – a naturally occurring molecule that causes blood vessels to dilate, limits cellular hypertrophy, and inhibits platelet aggregation.
Epoprostenol for Injection is an intravenous prostanoid vasodilator. Unlike other epoprostenol formulations approved for PAH, this formulation is stable at room temperature (77 F, 25 C), for up to 24 hours after it has been diluted and administered, making the use of frozen gel packs unnecessary.
US residents only: www.epoprostenol.com
Miglustat, the active ingredient of Zavesca®, is an orally available molecule with a large volume of distribution, which was developed for the treatment of type 1 Gaucher disease (GD1).
Pulmonary arterial hypertension (PAH) is a serious disease of the arteries connecting the lungs to the heart (the pulmonary arteries).
Digital ulcers are very painful and result in difficult-to-heal open sores that occur on fingers and toes.
Type 1 Gaucher disease, an inherited autosomal recessive disorder, is the most common disease among all inherited glycosphingolipid storage disorders, affecting approximately 7,000 patients worldwide.
Niemann-Pick type C disease is a rare genetic lysosomal storage disorder that causes severe, progressive neurological symptoms.
